Open AccessComparative risk of new‐onset diabetes mellitus for antihypertensive drugs: A network meta‐analysis
Author(s) -
Li Zimeng,
Li Yi,
Liu Yulong,
Xu Wenbo,
Wang Qing
Publication year - 2017
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.13108
Subject(s) - medicine , odds ratio , meta analysis , diabetes mellitus , confidence interval , nod , placebo , angiotensin converting enzyme , type 2 diabetes mellitus , calcium channel blocker , endocrinology , pharmacology , calcium , blood pressure , pathology , alternative medicine
New‐onset diabetes mellitus (NOD) refers to forms of diabetes mellitus that develop during the therapeutic processes of other diseases such as hypertension. This study has been conducted in a network meta‐analysis to compare antihypertensive drugs by identifying both the advantages and disadvantages on NOD by focusing on their respective effect rates. Odd ratios and corresponding 95% confidence intervals or credible intervals were calculated within pairwise and network meta‐analysis. A total of 38 articles with 224 140 patients were included to evaluate the preventive effect of hypertension drugs on NOD. From the network meta‐analysis it was evident that both angiotensin‐converting enzyme inhibitor as well as angiotensin receptor blocker treatments are associated with a lower risk of developing NOD compared with placebo, with ranking probabilities of 79.81% and 72.77%, respectively, while β‐blockers and calcium channel blockers may significantly increase the probability of developing NOD (β‐blockers: odds ratio, 2.18 [95% credible intervals: 1.36–3.50]; calcium channel blockers: odds ratio, 1.16 [95% credible intervals, 1.05–1.29]). In conclusion, angiotensin receptor blockers have an advantage over the other treatments regarding the NOD.